So high semaglutide pricing won't end up "bankrupting" the US medical system. It'll push an ever larger number of patients -- and more than a few well-meaning doctors, who already recommend things like BPC-157 -- into the gray market. That this would further delegitimize the medical establishment and FDA would be a well-deserved outcome.
Comments
Well, there you go, I guess.
So high semaglutide pricing won't end up "bankrupting" the US medical system. It'll push an ever larger number of patients -- and more than a few well-meaning doctors, who already recommend things like BPC-157 -- into the gray market. That this would further delegitimize the medical establishment and FDA would be a well-deserved outcome.